The insurance company has signed a deal with Assurance IQ for $2.35 billion and is willing to pay extra $1.15 billion in equity and cash. Prudential Financial, Inc., a Fortune 500 company that offers investment management, insurance and ot....

INBRX-101 is built to provide greater clinical activity to pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.     Inhibrx anticipates to unveil preliminary fun....

The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.   The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab....

The electronics giant is looking forward to putting forth the next-generation of its Smart Imaging Platform to offer hospitals a streamlined digital imaging work-flow. Sony, the leader in electronics for the professional and consumer marke....

Ad tracking firm Pathmatics has reportedly announced its plan to expand its data coverage of social advertising to Germany and the United Kingdom, by launching its flagship product Pathmatics Explorer in the regions. This announcement come....

The pharmaceutical company declared the completion of CTN submission to Japanese PMDA for TLX250-CDx. It is permitted to conduct Phase trials for renal cancer patients. Australia based clinical-stage biopharmaceutical firm Telix Pharma....

The burger features Beyond Meat’s 100% plant-based patty to be cooked in Carl’s Jr.’s char broiler Carl’s Jr., an American fast food restaurant chain, recently announced that it is planning to expand its partnership....

Automation Anywhere has received a total investment of approximately $550 million.   Automation Anywhere has 70% market share in Global Capability Centre space in India as well as a market share of 53% to 54% in Indian corporate sp....

The trial focuses on the effects of Prexigebersen when combined with Decitabine and Venetoclax on AML patients. Bio-Path Holdings, Inc., a biotechnology company renowned for creating therapeutic nucleic acid anticancer drugs, has recently ....

Leading biopharmaceutical expert CStone Pharmaceuticals has reportedly announced the first person in China to be dosed for the Phase I/II bridging trial of Avapritinib, discovered by Blueprint Medicines, a partner of CStone. This China-bas....